Orphazyme A/S
http://www.orphazyme.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Orphazyme A/S
Leo Looks For More Deals After Sealing Timber Buy
The Danish group’s pursuit of Timber, and its late-stage congenital ichthyosis therapy, has finally reached a successful conclusion and CEO Christophe Bourdon tells Scrip that the search is on for more innovative assets.
Zevra Rides To Rescue Of Cash-Strapped Acer
Acer's bank reserves have dwindled down to next to nothing following the failure of its menopause drug, osanetant, in a Phase II trial some six months ago. Enter Zevra, which is getting hold of the company and its just-launched urea cycle disorder drug, Olpruva, in what looks like a bargain.
A 3-Month Delay For A Better Label: US FDA User Fee Goal Extensions Are Usually Good News
Pink Sheet analysis finds big jump in the share of novel approvals that received PDUFA extensions, largely driven by clinical and safety data submissions.
Abcuro Raises $155m Series B Round For Clinical-Stage T-Cell Depleter
The company’s fresh cash will fund readouts for lead drug candidate ABC008 from a pivotal Phase II/III trial in inclusion body myositis and from Phase I/II studies in two other rare indications.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
- Other Names / Subsidiaries
-
- Orphazyme US, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice